secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001213900-25-071764
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year
--------------------------------------------------------------------------------

- Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.
- Tecarfarin has orphan drug and fast-track designations for ESKD+AFib, highlighting unmet need.
- Addresses critical gap: no proven anticoagulant for dialysis initiation period, which carries excess cardiovascular risk.
- CEO Quang X. Pham calls the study an important step forward for tecarfarin development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/0001213900-25-071764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025071764/ea0251809-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-071764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer